Loading…
Loading…
Structured register of government actions in the geoeconomic space — export controls, tariffs, sanctions, FDI screening, subsidies, industrial-policy laws — cross-referenced into the country, minerals, and ETF surface. Charter: docs/IPTM_CHARTER.md.
Severity 1-5 is the qualitative impact rating (1=minor, 5=structural). The bilateral-trade-grounded quant scorer is the next IPTM milestone. RBI (Register Breadth Index) is a complementary structural-breadth indicator from scripts/py/iptm/breadth.py; divergence between RBI and severity is itself informative (high-sev / low-RBI = strategic chokepoint; low-sev / high-RBI = broad but shallow). Every action has at least one primary source URL. Verify-or-don't-file. See also themes, timeline, graph, sankey, map, country exposure, sector exposure, material exposure (+ graph), weekly briefs, portfolio scan, escalation monitor, trans-shipment hubs. Internal triage tools (RSS-poller candidate feed, source-feed health) live under /admin/candidates + /admin/sources. Subscribe via Atom feed (accepts ?country=CN, ?material=lithium, ?issuer=BIS, ?type=export_control, ?etf=SOXX, ?company=NVDA, ?minSeverity=4, ?year=2026, ?q=…) or pull /api/iptm/actions.
On 9 September 2026 the UK Export Control Joint Unit published Notice to Exporters 2026/19, revoking and replacing the Open General Licence (Global Combat Air Programme) and issuing a new Open General Export Licence for "de minimis" exports under the UK-France-Germany-Spain Agreement on Defence Export Controls (published 10 December 2025). The new OGEL implements the Agreement's de-minimis principle: where UK-origin content does not exceed 20% of the value of a final defence system integrated by France, Germany or Spain, re-export/re-transfer authorisation is granted without case-by-case licensing, subject to a national-security carve-out. Both licences remove individual application requirements for a defined category of collaborative defence-programme exports rather than introducing new restrictions.
The UK Department of Health and Social Care added Co-codamol (30mg/500mg, all formulations) to its list of medicines that cannot be parallel-exported from the UK or hoarded, effective 28 January 2026. DHSC had issued a medicine supply warning for co-codamol 30mg/500mg on 12 January 2026, projecting limited supply into at least early June 2026. The restriction is issued under regulation 43(2) of the Human Medicines Regulations 2012; breach constitutes a wholesale dealer licence violation enforceable by the MHRA with licence suspension.
The UK Department of Health and Social Care added Aspirin (all strengths and forms) and Ifosfamide (1g/2g powder for solution for injection vials, a chemotherapy agent) to its list of medicines that cannot be parallel-exported from the UK or hoarded, effective 17 January 2026. Pharmacy trade press reported the addition followed manufacturing delays and raw- ingredient shortages that had left UK pharmacies short of aspirin stock. The restriction is issued under regulation 43(2) of the Human Medicines Regulations 2012; breach constitutes a wholesale dealer licence violation enforceable by the MHRA with licence suspension.
The UK Export Control (Amendment) (No. 2) Regulations 2025 (SI 2025/1197) entered into force on 16 December 2025, extending the UK's strategic export control regime to cover quantum computing hardware (ECCN-aligned 4A506), advanced and cryogenic semiconductor technologies (3A501, 3A504, 3B501), and associated software and technology categories. The regulations also transfer existing national controls on quantum and advanced semiconductor items from the Export Control Order 2008 into the UK's assimilated Dual-Use Regulation (retained EU 428/2009 as amended), harmonising the UK's dual-use schedule with Wassenaar Arrangement 2024 updates. The action is explicitly calibrated as "Wassenaar Minus One" — aligning UK controls with the US BIS (EAR / ECCN framework) and EU (Regulation 2021/821 as amended) without requiring multilateral consensus on each item. It is the first UK statutory instrument since Brexit to add substantial new technology-specific dual-use controls targeting advanced semiconductor and quantum capabilities.
The UK Department of Health and Social Care updated its list of medicines that cannot be parallel-exported from the UK or hoarded, adding Nelarabine (250mg/50ml solution for infusion vials, used in leukaemia/lymphoma treatment) and removing ten products including Atracurium, Cisatracurium and Erythromycin, effective 6 November 2025. The restriction is issued under regulation 43(2) of the Human Medicines Regulations 2012 to protect domestic patient supply; breach constitutes a wholesale dealer licence violation enforceable by the MHRA with licence suspension. This is one of the DHSC's routine multi-times-per-year revisions to a standing list rather than a one-off policy action.
The UK Department of Health and Social Care added five tuberculosis-treatment antimicrobials to its list of medicines that cannot be parallel-exported from the UK or hoarded, effective 17 July 2025: Rifampicin capsules/powder and solvent for infusion (all strengths), Pyrazinamide 500mg tablets, Rifampicin + Isoniazid 300mg/150mg tablets, Rifampicin + Isoniazid + Pyrazinamide 120mg/50mg/300mg tablets, and Voractiv tablets (all strengths). The restriction is issued under regulation 43(2) of the Human Medicines Regulations 2012; breach constitutes a wholesale dealer licence violation enforceable by the MHRA with licence suspension.
The Russia (Sanctions) (EU Exit) (Amendment) (No. 4) Regulations 2023 (SI 2023/1364) amend the Russia (Sanctions) (EU Exit) Regulations 2019 to prohibit UK persons from acquiring, importing, supplying or delivering listed Russian-origin metals and metal articles, delivering the Prime Minister's commitment to ban Russian copper, nickel and aluminium. Per law-firm summaries the list (a new Schedule 3BA) also covers lead, zinc, tin, tungsten, molybdenum, tantalum, magnesium, cobalt, antimony, manganese and further metals, and most provisions took effect on 15 December 2023 with a grace period for cargoes consigned before that date.
The UK government announced on 15 March 2022 that it would ban the export of high-end luxury goods to Russia in response to the invasion of Ukraine. The measure was implemented via new regulation 46B of the Russia (Sanctions) (EU Exit) Regulations 2019, inserted by the Russia (Sanctions) (EU Exit) (Amendment) (No. 8) Regulations 2022 (SI 2022/452), which was made on 13 April 2022 and came into force at 5pm on 14 April 2022. Regulation 46B prohibits the export, supply, or making available of luxury goods to, or for use in, Russia, covering goods with a sales price over £250 (excluding VAT) and vehicles over £42,000, spanning high-end fashion, works of art, jewellery, and vehicles, subject to licensing exceptions in Part 7.